Li Xingbin X Li

20030113817, Jun 19, 2003

Mar 22, 2002

10/103140

Li Li - Detroit MI, US
Li Yang - Windsor, CA

C12Q001/68
G01N033/567
C07H021/04
C12N009/00
C12P021/02
C07K016/40
C12N005/08

435/007210, 435/069100, 435/320100, 435/372000, 536/023200, 435/006000, 435/183000, 530/388260

A novel murine gene, designated Hemogen (hemopoietic gene) is sequentially expressed in active hematopoietic sites and downregulated during blood cell differentiation. Hemogen is a nuclear protein. A human homologue of Hemogen, named EDAG, which maps to chromosome 9q22, a leukemia breakpoint, exhibits also specific expression in hematopoietic tissues and cells. Hemogen and EDAG play an important role in hematopoietic development and neoplasms.

20040127442, Jul 1, 2004

Jul 3, 2003

10/613390

Zhifang Zhu - Columbia MO, US
Yuliang Cui - New York NY, US
Qingqing Ding - Houston TX, US
Li Li - Detroit MI, US
Zhi Wang - Houston TX, US

A61K048/00

514/044000

The invention provides compositions and methods for treating a proliferative disorder in a subject, comprising administering a proliferation-inhibiting amount of a single-stranded oligonucleotide to the subject, wherein said single-stranded oligonucleotide is capable of binding to one or more DNA-binding proteins or RNA primers in the subject, thereby treating the proliferative disorder. The invention also provides a method for modulating transcription in a cell, comprising administering an oligonucleotide to cells, wherein the oligonucleotide consists essentially of one or more regulatory elements, wherein the one or more regulatory elements are capable of binding a DNA-binding protein.